Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at the Stifel 2023 CNS Days
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023 , at 11:00 a.m.
View HTML
Toggle Summary Sage Therapeutics Appoints Jessica Federer to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.
View HTML
Toggle Summary Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the
View HTML
Toggle Summary Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2023-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023
View HTML
Toggle Summary Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
U.S. Food and Drug Administration (FDA)   accepts filing of New Drug Application (NDA) for zuranolone and grants Priority Review in the treatment of Major Depressive Disorder (MDD) and Postpartum Depression (PPD) following submission of rolling NDA in December 2022 Robust pipeline advancing nine
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m.
View HTML
Toggle Summary Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
Robust pipeline provides potential for long-term value creation, establishing Sage as a leader in brain health Rolling New Drug Application (NDA) submission for zuranolone in MDD and PPD complete, with potential for PDUFA date as early as the third quarter of 2023 if priority review is received and
View HTML
Toggle Summary Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2023-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January
View HTML